Hubungan Polimorfisme Genetik Nicotinic Acelycholine Recepttor CHRNB4 dengan Hasil VEP1 dan KVP pada Pasien Penyakit Paru Obstriktif Kronik
DOI:
https://doi.org/10.55606/jpikes.v6i1.7049Keywords:
CHRNB4 rs1948, COPD, FEV1, FVC, SpirometryAbstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory disorder resulting from interactions between environmental exposure, particularly cigarette smoke, and genetic susceptibility. Variants within thechromosome 15q25 locus encompassing the CHRNA5–CHRNA3–CHRNB4 gene cluster have been associated with smoking behavior, nicotine dependence, and smoking-related diseases, including COPD. The study aimed To evaluate the association between nicotinic acetylcholine receptor CHRNB4 rs1948 polymorphism and spirometric parameters, namely forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), in patients with COPD. This case–control study included 110 subjects (55 COPD patients and 55 controls). COPD diagnosis was established using post-bronchodilator spirometry according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations. 1 Genotyping of CHRNB4 rs1948 was performed using allele- specific polymerase chain reaction (PCR). Associations between genotype and severity of FEV1 and FVC impairment were analyzed using the Mann–Whitney U test. Mean predicted FEV1 in the COPD group was 38.03 ± 15.19, mean predicted FVC was 57.27 ± 17.03, and mean FEV1/FVC ratio was 50.98 ± 10.82. All COPD patients demonstrated an obstructive spirometric pattern. Compared with controls, COPD patients had significantly lower FEV1, FVC, and FEV1/FVC values (p<0.001). No significant association was observed between CHRNB4 rs1948 genotype and severity of FEV1 (p=0.771) or FVC (p=0.778) impairment. The CHRNB4 rs1948 polymorphism was not significantly associated with spirometric severity in COPD. The contribution of CHRNB4 to COPD may be mediated predominantly through smoking-related behavioral pathways rather than direct effects on lung volumes.
Downloads
References
Aaron, S. D., Tan, W. C., Bourbeau, J., Sin, D. D., Loves, R. H., MacNeil, J., et al. (2017). Diagnostic instability and reversals of COPD diagnosis in individuals with mild to moderate airflow obstruction. American Journal of Respiratory and Critical Care Medicine, 196(3), 306–314. https://doi.org/10.1164/rccm.201612-2531OC
Adams, T., & Morris, J. (2023). Nicotine addiction and smoking: Health effects and interventions. StatPearls Publishing.
Agarwal, A. K., Raja, A., & Brown, D. B. (2023). Chronic obstructive pulmonary disease. StatPearls Publishing.
Agustí, A., Calverley, P. M., Decramer, M., Stockley, R. A., & Wedzicha, J. A. (2014). Prevention of exacerbations in chronic obstructive pulmonary disease. COPD Foundation Journal, 1(2), 166–184. https://doi.org/10.15326/jcopdf.1.2.2014.0134
Agustí, A., Melen, E., DeMeo, D. L., et al. (2022). Pathogenesis of COPD: Understanding the contribution of gene–environment interactions across the lifespan. The Lancet Respiratory Medicine, 10, 512–524. https://doi.org/10.1016/S2213-2600(21)00555-5
Albert, P., Agustí, A., Edwards, L., Tal-Singer, R., Yates, J., & Bakke, P., et al. (2012). Bronchodilator responsiveness as a phenotypic characteristic of established COPD. Thorax, 67(8), 701–708. https://doi.org/10.1136/thoraxjnl-2011-201458
Allison, J. P., Hardy, R., Donaldson, G. C., Shaheen, S. O., Kuh, D., & Wedzicha, J. A. (2017). Combined impact of smoking and early life exposures on adult lung function trajectories. American Journal of Respiratory and Critical Care Medicine, 196, 1021–1030. https://doi.org/10.1164/rccm.201703-0506OC
Antariksa, B., Bahtiar, A., Wiyono, W. H., et al. (2023). PPOK: Pedoman diagnosis dan penatalaksanaan di Indonesia. PDPI.
Barnes, P. J. (2014). Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clinics in Chest Medicine, 35(1), 71–86. https://doi.org/10.1016/j.ccm.2013.10.004
Barnes, P. J. (2016). Inflammatory mechanisms in patients with COPD. Journal of Allergy and Clinical Immunology, 138, 16–27. https://doi.org/10.1016/j.jaci.2016.05.011
Barrie, E. S., Hartmann, K., Lee, S. H., Frater, J. T., Seweryn, M., Wang, D., et al. (2017). The CHRNA5/CHRNA3/CHRNB4 nicotinic receptor regulome: Genomic architecture, regulatory variants, and clinical associations. Human Mutation, 38(1), 112–119. https://doi.org/10.1002/humu.23135
Benowitz, N. L., & Henningfield, J. E. (1994). Establishing a nicotine threshold for addiction. JAMA, 271(15), 1173–1175.
Bhatt, S. P., Kim, Y. I., Harrington, K. F., et al. (2018). Smoking duration alone provides stronger risk estimate of chronic obstructive pulmonary disease than pack-years. Thorax, 73(5), 414–421. https://doi.org/10.1136/thoraxjnl-2017-210722
Bierut, L. J., et al. (2008). Variants in nicotinic receptors and risk for nicotine dependence. American Journal of Psychiatry, 165(9), 1163–1171. https://doi.org/10.1176/appi.ajp.2008.07111711
Brusselle, G. G., Joos, G. F., & Bracke, K. R. (2011). New insights into the immunology of chronic obstructive pulmonary disease. The Lancet, 378(9795), 1015–1026. https://doi.org/10.1016/S0140-6736(11)60988-4
Celli, B. R., Cote, C. G., Marin, J. M., et al. (2004). The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New England Journal of Medicine, 350(10), 1005–1012. https://doi.org/10.1056/NEJMoa021322
Cho, M. H., Castaldi, P. J., Wan, E. S., et al. (2012). A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 21(4), 947–957. https://doi.org/10.1093/hmg/ddr524
Cote, C. G., Dordelly, L. J., & Celli, B. R. (2007). Impact of COPD exacerbations on patient-centered outcomes. Chest, 131(3), 696–704. https://doi.org/10.1378/chest.06-1610
Dani, J. A., & De Biasi, M. (2001). Cellular mechanisms of nicotine addiction. Pharmacology Biochemistry and Behavior, 70(4), 439–446. https://doi.org/10.1016/S0091-3057(01)00652-9
Dani, J. A., & Harris, R. A. (2005). Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nature Neuroscience, 8(11), 1465–1470. https://doi.org/10.1038/nn1580
de Marco, R., Accordini, S., Marcon, A., et al. (2011). European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. American Journal of Respiratory and Critical Care Medicine, 183, 891–897. https://doi.org/10.1164/rccm.201007-1125OC
Dewi, A. L., Paramita, D. K., & Fachiroh, J. (2022). Tetra-primer amplification refractory mutation system (ARMS) PCR used to detect 3′UTR rs1948 mutation in CHRNB4. Indonesian Journal of Biotechnology, 27(1), 1–7. https://doi.org/10.22146/ijbiotech.64933
Eiserich, J. P., van der Vliet, A., Handelman, G. J., Halliwell, B., & Cross, C. E. (1995). Dietary antioxidants and cigarette smoke-induced biomolecular damage: A complex interaction. American Journal of Clinical Nutrition, 62, 1490S–1500S. https://doi.org/10.1093/ajcn/62.6.1490S
Fagerström, K. (2012). Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine & Tobacco Research, 14(1), 75–78. https://doi.org/10.1093/ntr/ntr137
Fan, H., Wu, F., Liu, J., et al. (2021). Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: A systematic review and meta-analysis. Annals of Translational Medicine, 9, 390. https://doi.org/10.21037/atm-20-4576
Flora, A. V., Zambrano, C. A., Gallego, X., et al. (2013). Functional characterization of SNPs in the CHRNA3/B4 intergenic region associated with drug behaviors. Brain Research, 1529, 1–12. https://doi.org/10.1016/j.brainres.2013.07.017
Forey, B. A., Thornton, A. J., & Lee, P. N. (2011). Systematic review with meta-analysis of smoking and COPD. BMC Pulmonary Medicine, 11, 36. https://doi.org/10.1186/1471-2466-11-36
Gaddis, M. A., et al. (2007). The CHRNA5/CHRNA3/CHRNB4 gene cluster and susceptibility to chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 176(4), 339–345.
Galkina, E., & Ley, K. (2009). Immune and inflammatory mechanisms of atherosclerosis. Annual Review of Immunology, 27, 165–197. https://doi.org/10.1146/annurev.immunol.021908.132620
Gallego, X., Cox, R. J., Laughlin, J. R., Stitzel, J. A., & Ehringer, M. A. (2013). Alternative CHRNB4 3′-UTRs mediate the allelic effects of SNP rs1948 on gene expression. PLoS One, 8(5), e63699. https://doi.org/10.1371/journal.pone.0063699
Gallego, X., Molas, S., Amador-Arjona, A., Marks, M. J., Robles, N., Butt, C. M., et al. (2012). Overexpression of the CHRNB4 gene in mice increases the loss of dopaminergic neurons after MPTP treatment. Neuropharmacology, 63(7), 1256–1266.
Gershon, A. S., Warner, L., Cascagnette, P., Victor, J. C., & To, T. (2011). Lifetime risk of developing chronic obstructive pulmonary disease: A longitudinal population study. The Lancet, 378, 991–996. https://doi.org/10.1016/S0140-6736(11)60990-2
Global Initiative for Chronic Obstructive Lung Disease. (2014). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org
Global Initiative for Chronic Obstructive Lung Disease. (2023). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD.
Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report (v1.0, 15 Nov 2024). GOLD.
Global Initiative for Chronic Obstructive Lung Disease. (2026). Global strategy for the prevention, diagnosis and management of chronic obstructive pulmonary disease: 2026 report. GOLD.
Graham, B. L., et al. (2019). Standardization of spirometry 2019 update. American Journal of Respiratory and Critical Care Medicine, 200(8), e70–e88. https://doi.org/10.1164/rccm.201908-1590ST
Grippi, M. A., Antin-Ozerkis, D. E., Dela Cruz, C. S., Kotloff, R., Kotton, C. N., & Pack, A. I. (2022). Fishman's pulmonary diseases and disorders (6th ed.). McGraw-Hill.
Guder, G., Brenner, S., Angermann, C. E., Ertl, G., Held, M., Sachs, A. P., et al. (2012). GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort study. Respiratory Research, 13(1), 13. https://doi.org/10.1186/1465-9921-13-13
Han, M. K., Agusti, A., Celli, B. R., Criner, G. J., Halpin, D. M. G., Roche, N., et al. (2021). From GOLD 0 to pre-COPD. American Journal of Respiratory and Critical Care Medicine, 203, 414–423. https://doi.org/10.1164/rccm.202008-3328PP
Han, M. K., Ye, W., Wang, D., White, E., Arjomandi, M., Barjaktarevic, I. Z., et al. (2022). Bronchodilators in tobacco-exposed persons with symptoms and preserved lung function. New England Journal of Medicine, 387, 1173–1184. https://doi.org/10.1056/NEJMoa2204752
Hecht, S. S. (1999). Tobacco smoke carcinogens and lung cancer. Journal of the National Cancer Institute, 91(14), 1194–1210. https://doi.org/10.1093/jnci/91.14.1194
Henderson, J., et al. (2016). Childhood respiratory infections and the development of asthma and COPD: The role of early-life exposures. Thorax, 71(9), 803–811.
Hernández-Pérez, A., García-Gómez, L., Robles, R. E., Thirion-Romero, I., Osio-Echánove, J., Rodríguez-Llamazares, S., et al. (2023). Addiction to tobacco smoking and vaping. [Journal unclear], 75(3). https://doi.org/10.24875/RIC.23000117
Higham, A., & Singh, D. (2019). Chronic inflammation in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 14, 1611–1620.
Hnizdo, E., Sullivan, P. A., Bang, K. M., & Wagner, G. (2002). Association between COPD and employment by industry and occupation in the US population. American Journal of Epidemiology, 156, 738–746. https://doi.org/10.1093/aje/kwf105
Hogg, J. C., & Timens, W. (2009). The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology, 4, 435–459. https://doi.org/10.1146/annurev.pathol.4.110807.092145
Improgo, M. R., Scofield, M. D., Tapper, A. R., & Gardner, P. D. (2010). From smoking to lung cancer: The CHRNA5/A3/B4 connection. Oncogene, 29(35), 4874–4884. https://doi.org/10.1038/onc.2010.256
Janson, C. (2014). Exacerbations in chronic obstructive pulmonary disease. The Lancet Respiratory Medicine, 2(4), 279–280.
Jiang, J., Li, X., Hu, A., Zhou, G., Gao, Y., Xu, C., et al. (2025). Nicotine and neuronal nicotinic acetylcholine receptors: Unraveling the mechanisms of nicotine addiction. Frontiers in Neuroscience, 19. https://doi.org/10.3389/fnins.2025.1670883
Jones, J. G., Minty, B. D., Lawler, P., et al. (1980). Increased alveolar epithelial permeability in cigarette smokers. The Lancet, 1, 66–68. https://doi.org/10.1016/S0140-6736(80)90493-6
Kaur-Knudsen, D., Bojesen, S. E., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2011). Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related diseases. Journal of Clinical Oncology, 29(21), 2875–2882. https://doi.org/10.1200/JCO.2010.32.9870
Kementerian Kesehatan Republik Indonesia. (2019a). Laporan riset kesehatan dasar (Riskesdas) 2018: Hasil utama.
Kementerian Kesehatan Republik Indonesia. (2019b). Pedoman nasional pelayanan kedokteran tata laksana penyakit paru obstruktif.
Kirkham, P. A., & Barnes, P. J. (2020). Oxidative stress in COPD. Redox Biology, 33, 101485.
Lassi, G., Taylor, A. E., Timpson, N. J., & Munafò, M. R. (2016). The CHRNA5-A3-B4 gene cluster and smoking. Trends in Neurosciences, 39(12), 851–861. https://doi.org/10.1016/j.tins.2016.10.005
Lee, J., Bloom, E. R., & Leischow, S. J. (2016). Smoking behavior and dependence among smokers with and without COPD. Nicotine & Tobacco Research, 18(5), 1050–1056.
Li, X., Ortega, V. E., Ampleford, E. J., et al. (2018). Genome-wide association study of lung function and clinical implication in heavy smokers. BMC Medical Genetics, 19(1), 134. https://doi.org/10.1186/s12881-018-0656-z
Liu, Q., Liu, Z., Li, S., et al. (2018). Association and cis-mQTL analysis of variants in CHRNA genes with nicotine dependence. Translational Psychiatry, 8(1), 146. https://doi.org/10.1038/s41398-018-0130-x
MacNee, W. (2006). COPD: Pathology, pathogenesis and pathophysiology. BMJ, 332(7551), 1202–1204. https://doi.org/10.1136/bmj.332.7551.1202
Melen, E., et al. (2006). Polymorphism in CHRNA5 and CHRNA3 associated with COPD. American Journal of Human Genetics, 78(5), 936–943.
Meza, D., Khuder, B., Bailey, J. J., et al. (2021). Mortality from COVID-19 in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 16, 2323–2326. https://doi.org/10.2147/COPD.S318000
Munafò, M. R., Timpson, N., et al. (2012). Association between genetic variants on chromosome 15q25 locus and tobacco exposure. Journal of the National Cancer Institute, 104(10), 740–748. https://doi.org/10.1093/jnci/djs191
Nedeljkovic, I., Carlsen, K. C. L., Lødrup Carlsen, K. C., et al. (2018). Genetic susceptibility, smoking, and COPD: A review. Respiratory Medicine, 137, 1–12.
Ortiz-Quintero, B., Martinez-Espinosa, I., & Perez-Padilla, R. (2022). Mechanisms of lung damage due to biomass-smoke exposure. Cells, 12(1), 67. https://doi.org/10.3390/cells12010067
Pillai, S. G., Ge, D., Zhu, G., et al. (2009). A genome-wide association study in COPD. PLoS Genetics, 5(3), e1000421. https://doi.org/10.1371/journal.pgen.1000421
Quan, C., et al. (2020). CHRNB4 polymorphisms and smoking behavior in Asian populations. Frontiers in Genetics, 11, 512.
Repapi, E., Sayers, I., Wain, L. V., et al. (2010). Genome-wide association study identifies loci associated with lung function. Nature Genetics, 42(1), 36–44. https://doi.org/10.1038/ng.501
Rossaki, F. M., Hurst, J. R., van Gemert, F., et al. (2021). Strategies for COPD in low- and middle-income countries. Expert Review of Respiratory Medicine, 15(12), 1563–1577. https://doi.org/10.1080/17476348.2021.1985762
Saccone, N. L., et al. (2010). Multiple loci at chromosome 15q25.1 affect smoking quantity. Human Molecular Genetics, 19(14), 2868–2876.
Saccone, N. L., Wang, J. C., Breslau, N., et al. (2009). Nicotinic receptor gene cluster and nicotine dependence. Cancer Research, 69(17), 6848–6856. https://doi.org/10.1158/0008-5472.CAN-09-0786
Saccone, S. F., et al. (2007). Nicotinic receptor genes and nicotine dependence. Human Molecular Genetics, 16(1), 36–49. https://doi.org/10.1093/hmg/ddl438
Saetta, M. (1999). Airway inflammation in COPD. American Journal of Respiratory and Critical Care Medicine, 160, S17–S20. https://doi.org/10.1164/ajrccm.160.supplement_1.6
Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., et al. (2019). Genetic landscape of COPD. Nature Genetics, 51, 494–505. https://doi.org/10.1038/s41588-018-0342-2
Sansone, L., Milani, F., Fabrizi, R., et al. (2023). Nicotine: From discovery to biological effects. International Journal of Molecular Sciences, 24(19), 14570. https://doi.org/10.3390/ijms241914570
Schermer, T. R., Robberts, B., Crockett, A. J., et al. (2016). Diagnosis of COPD and spirometry. NPJ Primary Care Respiratory Medicine, 26, 16059. https://doi.org/10.1038/npjpcrm.2016.59
Sethi, S., & Murphy, T. F. (2021). COPD: Pathogenesis and pathophysiology. Clinics in Chest Medicine, 42(3), 431–444.
Silverman, E. K., Vestbo, J., Agusti, A., et al. (2011). Genetics of COPD. COPD, 8, 121–135. https://doi.org/10.3109/15412555.2011.558864
Smith, K. R., et al. (2009). Indoor air pollution from household fuels. The Lancet, 374(9700), 1844–1854.
Stephens, S. H., Hartz, S. M., Hoft, N. R., et al. (2013). CHRNA gene cluster and smoking onset. Genetic Epidemiology, 37(8), 846–859. https://doi.org/10.1002/gepi.21760
Stephens, S. H., Hartz, S. M., Zhang, X., et al. (2013). CHRNA gene cluster and nicotine phenotypes. Addiction Biology, 18(2), 257–269.
Tager, I. B., Ngo, L., & Hanrahan, J. P. (1995). Maternal smoking and lung function. American Journal of Respiratory and Critical Care Medicine, 152, 977–983. https://doi.org/10.1164/ajrccm.152.3.7663813
Tarigan, A. P. (2022). Buku ajar faal paru. Program Studi Pulmonologi & Kedokteran Respirasi.
Tashkin, D. P. (2008). COPD: Current scientific understanding and therapeutic approaches. Springer.
Thorgeirsson, T. E., et al. (2010). Variant associated with nicotine dependence. Nature, 463(7278), 518–522.
Tsuchiya, M., Asada, A., Kasahara, E., et al. (2002). Smoking and antioxidant levels. Circulation, 105, 1155–1157. https://doi.org/10.1161/hc1002.105935
Van Dijk, W., Tan, W., Li, P., et al. (2015). FEV1/FVC definitions in COPD. Annals of Family Medicine, 13(1), 41–48. https://doi.org/10.1370/afm.1714
Wain, L. V., Shrine, N., Artigas, M. S., et al. (2020). Genome-wide association analyses for COPD. Nature Genetics, 52(2), 116–117.
Weinberger, S. E., Cockrill, B. A., & Mandel, J. (2019). Principles of pulmonary medicine (7th ed.). Elsevier.
Weiss, R. B., Baker, T. B., Cannon, D. S., et al. (2008). CHRNA gene region and nicotine addiction. PLoS Genetics, 4(7), e1000125. https://doi.org/10.1371/journal.pgen.1000125
Wheaton, A. G., Liu, Y., Croft, J. B., et al. (2017). COPD and smoking status. MMWR, 68(24), 533–538. https://doi.org/10.15585/mmwr.mm6824a1
Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., et al. (2012). Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacology & Therapeutics, 92(4), 414–417. https://doi.org/10.1038/clpt.2012.96
Wilk, J. B., Chen, T. H., Gottlieb, D. J., et al. (2009). GWAS of pulmonary function. PLoS Genetics, 5(3), e1000429. https://doi.org/10.1371/journal.pgen.1000429
Wilk, J. B., et al. (2012). GWAS and airflow obstruction. American Journal of Respiratory and Critical Care Medicine, 186(7), 622–632. https://doi.org/10.1164/rccm.201202-0366OC
Wise, R. A. (2024). Chronic obstructive pulmonary disease. MSD Manual Professional Edition.
Wisman, B. A., Mardhiyah, R., & Tenda, E. D. (2015). Pendekatan diagnostik PPOK GOLD D. Indonesian Journal of Chest, 2(4), 180–190.
World Health Organization. (2024). Global adult tobacco survey Indonesia report 2021.
Yang, J., Wang, H., Chen, H., Hou, H., & Hu, Q. (2024). Genetic polymorphisms and nicotine dependence. Heliyon, 10(12), e33158. https://doi.org/10.1016/j.heliyon.2024.e33158
Yang, K., McLaughlin, I., Shaw, J. K., Quijano-Cardé, N., Dani, J. A., & De Biasi, M. (2023). CHRNA5 variation and dopaminergic neurons. Neuropharmacology, 235, 109547. https://doi.org/10.1016/j.neuropharm.2023.109547
Young, R. P., & Hopkins, R. J. (2020). Prevention of COPD. American Journal of Respiratory and Critical Care Medicine, 190, 7. https://doi.org/10.1164/rccm.201405-0883LE
Zhang, J., Lou, D., & Juo, S. H. H. (2011). Nicotinic receptor variants and COPD. Respiratory Research, 12, 158. https://doi.org/10.1186/1465-9921-12-158
Zhang, X., Yan, D., Shi, W., Li, J., Qin, C., Guo, Y., et al. (2018). CHRNA polymorphisms and COPD risk. Journal of Clinical Laboratory Analysis, 32(1), e22160.
Zhao, Z., Zhu, Q., Dou, S., et al. (2015). CHRNA variants and lung function. Respiration, 90(3), 210–219.
Zuo, Y., et al. (2021). Nicotinic receptor signaling in airway inflammation. Respiratory Research, 22, 1–12.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jurnal Pengabdian Ilmu Kesehatan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
